In pharmaceutical product liability cases, individual causation must be established on the balance of probabilities and cannot rely solely on epidemiological evidence of increased population-level risk; a contested physiological hypothesis combined with epidemiological data showing doubled relative risk is insufficient to prove that a specific plaintiff's injury was caused by the drug.
The full text is available to signed-in members, including the 48 later cases that cite this judgment.
9 of the 48 citing cases carry a classified treatment. How each court treated it is available to signed-in members.